InceptionR’s Haemonetics HAE Stock Holding History

InceptionR’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,688	Closed	-$471K	–	502
2023 Q1	$471K	Buy	+5,688	New	+$460K	0.15%	253

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

InceptionR's HAE Position: Q2 2023 in Review

InceptionR sold out of Haemonetics (HAE) in Q2 2023, closing a stake of 5,688 shares — an estimated $471K sold.

InceptionR first reported a position in HAE in Q1 2023 and held it in 1 quarter. The position peaked at $471K in Q1 2023. 296 funds tracked by Wall St. Rank hold HAE as of Q2 2023.

InceptionR reported no remaining Haemonetics position as of Q2 2023 after selling out during the quarter.
InceptionR sold 5,688 Haemonetics shares in Q2 2023, an estimated $471K.
InceptionR first reported a position in Haemonetics in Q1 2023 and held it in 1 quarter.
InceptionR's Haemonetics position peaked at $471K in Q1 2023.
296 funds tracked by Wall St. Rank held Haemonetics as of Q2 2023.

Based on InceptionR's 13F filing for Q2 2023, filed 11 Aug 2023.